Form 8-K - Current report:
SEC Accession No. 0001193125-25-121824
Filing Date
2025-05-16
Accepted
2025-05-16 17:26:51
Documents
17
Period of Report
2025-05-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d45771d8k.htm   iXBRL 8-K 30447
2 EX-1.1 d45771dex11.htm EX-1.1 287129
3 EX-4.1 d45771dex41.htm EX-4.1 63791
4 EX-5.1 d45771dex51.htm EX-5.1 15563
8 GRAPHIC g45771g0515230020514.jpg GRAPHIC 2199
  Complete submission text file 0001193125-25-121824.txt   625228

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA atra-20250514.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20250514_lab.xml EX-101.LAB 17235
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20250514_pre.xml EX-101.PRE 10814
19 EXTRACTED XBRL INSTANCE DOCUMENT d45771d8k_htm.xml XML 3515
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 25960705
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)